Ashland Global vs Chemours
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Ashland Global and Chemours side by side, using each one’s latest annual report. Here is what stands out:
- Chemours is the larger business, with $5.8B of revenue in fiscal 2025 against $1.8B for Ashland Global, about 3.2 times as much.
- Chemours grew revenue faster (0.5%, against −13.7%).
- Ashland Global turned more of its sales into free cash flow (2.0% FCF margin, against 0.9%).
- Chemours earned a higher return on the capital invested in it (−0.2%, against −17.5%).
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
Ashland Global
ASH
5/9
Gross marginFCF marginReturn on equityPiotroski F-scoreShare count change
Chemours
CC
4/9
Revenue growth5-year growthNet marginReturn on capital
Side by side
Best in the row
| Latest fiscal year | ASH FY25 | CC FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.3B | $1.9B |
| Revenue | $1.8B | $5.8B |
| Free cash flow | $36.0M | $51.0M |
| Net income | −$845M | −$386M |
| Growth | ||
| Revenue growth | −13.7% | 0.5% |
| 5-year growth | −2.0% | 3.2% |
| Share count change | −8.0% | 0.0% |
| Profitability | ||
| Gross margin | 30.1% | 15.5% |
| Operating margin | −42.5% | — |
| Net margin | −46.3% | −6.7% |
| FCF margin | 2.0% | 0.9% |
| Return on capital | −17.5% | −0.2% |
| Return on equity | −35.4% | −94.0% |
| Balance sheet | ||
| Net debt | $1.2B | $3.5B |
| Net debt / EBITDA | — | 10.6x |
| Dividends and buybacks | $176M | $78.0M |
| Valuation & quality | ||
| P/E | 68.9x | — |
| Piotroski F-score | 5 | 4 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.

